A Phase 2 interventional study of Tovorafenib in Low-grade Glioma and Advanced Solid Tumor, sponsored by Day One Biopharmaceuticals, Inc.. Recruiting at 35 sites in 11 countries. Open to participants aged 6 Months to 25 Years. Per ClinicalTrials.gov, last updated 2025-04-10.
Sponsored by Day One Biopharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified through molecular assays as routinely performed at Clinical Laboratory Improvement Amendments (CLIA) of 1988 or other similarly certified laboratories prior to enrollment into any of the arms. The study will consist of a screening period, a treatment period, a long-term extension phase, end of treatment (EOT) visit(s), a safety follow-up visit, and long-term follow-up assessments.
Day One Biopharmaceuticals, Inc. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion/exclusion criteria as stipulated by protocol may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with recurrent or progressive low-grade glioma will receive 420 milligrams/meters square (mg/m\^2) of tovorafenib weekly according to dose rounding guidelines and according to their baseline body surface area (BSA).
Drug: Tovorafenib
Participants with recurrent or progressive low-grade glioma will receive 420 mg/m\^2 of tovorafenib weekly according to dose rounding guidelines and according to their baseline BSA.
Drug: Tovorafenib
Participants with advanced solid tumors will receive 420 mg/m\^2) of tovorafenib weekly according to dose rounding guidelines and according to their baseline BSA.
Drug: Tovorafenib
Tovorafenib is an oral Type II RAF kinase inhibitor available in 100 mg immediate-release tablet or 25 mg/milliliter (mL) powder for reconstitution.
Also known as: DAY101
Arm 1: Overall response rate
ORR is defined as percentage of participants with best overall confirmed response of complete response (CR) or partial response (PR) by the Response Assessment in Neuro-Oncology - high-grade glioma (RANO-HGG) criteria.
Time frame: Up to 48 months
Arm 2: Number of participants reporting adverse events
An adverse event (AE) is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to 48 months
Arm 2: Number of participants with clinically significant changes in clinical chemistry parameters
Time frame: Up to 48 months
Arm 2: Number of participants with clinically significant changes in hematology parameters
Time frame: Up to 48 months
Arm 3: Overall response rate
Determined by the treating investigator and measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or RANO-HGG criteria, as appropriate.
Time frame: Up to 48 months
Arm 1 and 3: Number of participants reporting adverse events
An adverse event (AE) is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to 48 months
Arm 1 and 3: Number of participants with clinically significant changes in clinical chemistry parameters
Time frame: Up to 48 months
Arm 1 and 3: Number of participants with clinically significant changes in hematology parameters
Time frame: Up to 48 months
Arm 1: Area under the concentration-time curve (AUC) of Tovorafenib
Time frame: Cycle 1: Day 1 and Day 15; Cycles 2, 4, 7, 10 and 13: Day 1
Arm 1: Minimum drug concentration (Cmin)
Time frame: Cycle 1: Day 1 and Day 15; Cycles 2, 4, 7, 10 and 13: Day 1
Arm 1: Change from Baseline QT interval corrected for heart rate by Fridericia's formula (ΔQTcF)
Time frame: Baseline to 48 months
Arm 1: Change from Baseline PR interval (ΔPR)
Time frame: Baseline to 48 months
Arm 1: Change from Baseline QRS interval (ΔQRS)
Time frame: Baseline to 48 months
Arm 1: Change from baseline heart rate (ΔHR)
Time frame: Baseline to 48 months
Arm 1: Change in electrocardiogram (ECG) waveform morphology
Time frame: Baseline to 48 months
Arm 1 and Arm 2: Overall response rate
ORR is defined as percentage of participants with best overall confirmed response of CR or PR by the RANO-HGG criteria.
Time frame: Up to 48 months
Arm 1, Arm 2 and Arm 3: Overall response rate in Pediatric participants
ORR is defined as percentage of participants with best overall confirmed response of CR or PR or minor response (MR) by Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria.CR or PR by RECIST v1.1 criteria.
Time frame: Up to 48 months
Arm 1, Arm 2 and Arm 3: duration of progression-free survival (PFS)
PFS as defined by the time following initiation of tovorafenib to progression or death in participants treated with tovorafenib measured by RECIST v1.1, RAPNO, or RANO-HGG criteria as determined by the treating investigator and an IRC.
Time frame: Up to 48 months
Arm 1, Arm 2 and Arm 3: Duration of response (DOR)
DOR as defined by the length of response in participants with best overall confirmed response of CR or PR or MR and measured by RANO-HGG, RAPNO, and/or RECIST v1.1 criteria, as applicable.
Time frame: Up to 48 months
Arm 1, Arm 2 and Arm 3: Time to response (TTR)
TTR as defined as the time to first response following initiation of tovorafenib in participants with best overall confirmed response of CR or PR measured by RECIST v1.1 or RANO-HGG criteria, as applicable.
Time frame: Up to 48 months
Arm 1, Arm 2 and Arm 3: Clinical benefit rate (CBR)
CBR as defined as participants with BOR of CR, PR or stable disease (SD) measured by RECIST v1.1 or RANO-HGG, as applicable, and lasting 12 months or more following initiation of tovorafenib.
Time frame: Up to 48 months
Arm 1 and Arm 2: Duration of overall survival
Overall survival as defined by the time following initiation of tovorafenib to death of any cause in participants treated with tovorafenib.
Time frame: Up to 48 months
Arm 1: Change from baseline in best corrected visual acuity (BCVA) outcomes
Time frame: Baseline to 48 months
Arm 1: Changes in molecular analysis of cells obtained from archival tissue
Time frame: At Screening
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
PDFs hosted by the registry, ClinicalTrials.gov.
Started Apr 2021 (actual). Primary completion is estimated for May 2027, 73 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tovorafenib
Day One Biopharmaceuticals, Inc.